As of the first of this year, we are Cyclomedical International, Inc., a Tennessee company with affiliated companies Cyclomedical Applications Group, LLC, in the United States; Cyclomedical Applications FZE in the United Arab Emirates (UAE); and Cyclomedical Applications Group, Ltd, in Doha, Qatar, with worldwide operation from our office in Knoxville.  The new business structure will better support expanded services, according to COO Richard O. Deaderick.

As the only independent service provider of its kind, Cyclomedical provides global radiopharmaceutical expertise such as consulting services for Positron Emission Tomography (PET) research and clinical facilities, site planning and project management services for radiopharmaceutical production sites, operation of cyclotron production facilities for diagnostic imaging agents including SPECT, and performs Quality Control laboratory installations for major cyclotron manufacturers worldwide, from Viet Nam to Ecuador. 

Cyclomedical has been the operator of cyclotron facilities in the U.S. since 2003 and in the Gulf (GCC) Region since 2010, supplying the Tawam Medical Imaging Centre (Al Ain, UAE) and Hamad Hospital (Doha, Qatar) with PET radiopharmaceuticals for cancer diagnosis and staging.  Consulting is a major component of Cyclomedical’s services, and has included international clients as well as research institutions in the U.S.

Dr. James Lamb, Ph.D., President and CEO, reports that Cyclomedical International is in process of forming an entity in Muscat, Oman, to operate the National Molecular Imaging Centre (NMIC).  Cyclomedical is providing project management on design and construction of this cyclotron facility, scheduled for completion mid-year, for contractor Muscat Pharmacy and Stores.  NMIC will be affiliated with the Royal Hospital.  “This is the best available technology for diagnosis and targeted treatment for cancer and means better outcomes for patients who have access to the technology”, says Dr. Lamb.